380 related articles for article (PubMed ID: 29488214)
21. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
22. Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells.
Takezawa Y; Izumi K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Natsagdorj A; Kadono Y; Keller ET; Zhang J; Mizokami A
Anticancer Res; 2018 Apr; 38(4):2045-2055. PubMed ID: 29599322
[TBL] [Abstract][Full Text] [Related]
23. Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer.
Kawata H; Kamiakito T; Nakaya T; Komatsubara M; Komatsu K; Morita T; Nagao Y; Tanaka A
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):219-227. PubMed ID: 27329245
[TBL] [Abstract][Full Text] [Related]
24. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
25. PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression.
Li Y; Lv L; Ye M; Xie N; Fazli L; Wang Y; Wang W; Yang S; Ni Q; Chen J; Guo X; Zhao Y; Xue G; Sha J; Dong X; Zhang L
Oncogene; 2024 May; 43(21):1631-1643. PubMed ID: 38589675
[TBL] [Abstract][Full Text] [Related]
26. Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors.
Singh V; Jaiswal PK; Ghosh I; Koul HK; Yu X; De Benedetti A
Int J Cancer; 2019 Aug; 145(4):1055-1067. PubMed ID: 30737777
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Androgen Receptor Signaling Promotes Prostate Cancer Cell Migration via Upregulation of Annexin A1 Expression.
Yang W; Wang K; Ma J; Hui K; Lv W; Ma Z; Huan M; Luo L; Wang X; Li L; Chen Y
Arch Med Res; 2021 Feb; 52(2):174-181. PubMed ID: 33059953
[TBL] [Abstract][Full Text] [Related]
28. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
29. Targeting Prostate Cancer, the 'Tousled Way'.
Bhoir S; De Benedetti A
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446279
[TBL] [Abstract][Full Text] [Related]
30. Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy.
Wan X; Pu H; Huang W; Yang S; Zhang Y; Kong Z; Yang Z; Zhao P; Li A; Li T; Li Y
Oncotarget; 2016 Aug; 7(32):51284-51300. PubMed ID: 27323416
[TBL] [Abstract][Full Text] [Related]
31. Nur77 suppression facilitates androgen deprivation-induced cell invasion of prostate cancer cells mediated by TGF-β signaling.
Wu J; Sun H; Yang X; Sun X
Clin Transl Oncol; 2018 Oct; 20(10):1302-1313. PubMed ID: 29594945
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
33. Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer.
Sasaki T; Ishii K; Iwamoto Y; Kato M; Miki M; Kanda H; Arima K; Shiraishi T; Sugimura Y
Lab Invest; 2016 Mar; 96(3):338-49. PubMed ID: 26641067
[TBL] [Abstract][Full Text] [Related]
34. Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer.
Nishiyama T
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):179-90. PubMed ID: 22269996
[TBL] [Abstract][Full Text] [Related]
35. Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells.
Kim J; Park S; Kim S; Ryu S; Hwang H; Cho S; Han Y; Kim J; Park Y; Lee EK; Lee M
Prostate; 2024 Jun; 84(9):814-822. PubMed ID: 38558458
[TBL] [Abstract][Full Text] [Related]
36. Physalins A and B inhibit androgen-independent prostate cancer cell growth through activation of cell apoptosis and downregulation of androgen receptor expression.
Han H; Qiu L; Wang X; Qiu F; Wong Y; Yao X
Biol Pharm Bull; 2011; 34(10):1584-8. PubMed ID: 21963499
[TBL] [Abstract][Full Text] [Related]
37. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
Cai Y; Lee YF; Li G; Liu S; Bao BY; Huang J; Hsu CL; Chang C
Int J Cancer; 2008 Jul; 123(1):195-201. PubMed ID: 18386814
[TBL] [Abstract][Full Text] [Related]
38. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
[TBL] [Abstract][Full Text] [Related]
39. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
D'Antonio JM; Ma C; Monzon FA; Pflug BR
Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]